Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Depreciation and Depletion (2022 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Depreciation and Depletion for 4 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation and Depletion fell 85.71% year-over-year to $100000.0, compared with a TTM value of $3.2 million through Sep 2025, up 18.52%, and an annual FY2024 reading of $2.6 million, up 13.04% over the prior year.
  • Depreciation and Depletion was $100000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $1.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.3 million in Q2 2025 and bottomed at $100000.0 in Q3 2025.
  • Average Depreciation and Depletion over 4 years is $573333.3, with a median of $600000.0 recorded in 2024.
  • The sharpest move saw Depreciation and Depletion skyrocketed 150.0% in 2023, then crashed 85.71% in 2025.
  • Year by year, Depreciation and Depletion stood at $300000.0 in 2022, then surged by 133.33% to $700000.0 in 2023, then dropped by 14.29% to $600000.0 in 2024, then plummeted by 83.33% to $100000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for BRNS at $100000.0 in Q3 2025, $1.3 million in Q2 2025, and $1.2 million in Q1 2025.